<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="252">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547127</url>
  </required_header>
  <id_info>
    <org_study_id>GC2003</org_study_id>
    <secondary_id>2020-001299-14</secondary_id>
    <nct_id>NCT04547127</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if Convalescent anti-severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2) Methylene Blue Treated (MBT) plasma plus Standard Medical
      Treatment (SMT) can reduce all-cause mortality versus SMT alone in hospitalized participants
      with COVID-19 requiring admission to the intensive care unit (ICU) through Day 29.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality Rate</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in National Early Warning Score (NEWS)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Response as Assessed by NEWS ≤ 2 Maintained for 24 hours</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ICU Discharge</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of All Oxygen Use</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Value Change from Baseline in Ordinal Scale</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Ordinal Scale</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale</measure>
    <time_frame>Day 15 and Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Convalescent anti-SARS-CoV-2 MBT Plasma + SMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 consecutive transfusions of 200 to 250 milliliters (ml) of ABO-compatible convalescent plasma with each unit of plasma, obtained from the same convalescent donor, which will be administered on Day 1 using standard procedures for administration of fresh frozen plasma. Participants weighing less than 45 kilograms (kg) will receive two transfusions of 10 ml of convalescent plasma per kilogram of body weight with each unit of plasma obtained from the same convalescent donor. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent anti-SARS-CoV-2 MBT Plasma</intervention_name>
    <description>Intravenous infusion.</description>
    <arm_group_label>Convalescent anti-SARS-CoV-2 MBT Plasma + SMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Medical Treatment</intervention_name>
    <description>SMT</description>
    <arm_group_label>Convalescent anti-SARS-CoV-2 MBT Plasma + SMT</arm_group_label>
    <arm_group_label>Standard Medical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized male or female subjects of ≥ 18 years of age at time of Screening who are
             being treated in the intensive care unit (ICU) for COVID-19 for not longer than 48
             hours or for whom a decision has been made that COVID-19 disease severity warrants ICU
             admission.

          -  Subject (or a legal representative or a nearest relative or a relative by marriage, as
             appropriate) provides informed consent (ICF) prior to initiation of any study
             procedures.

          -  Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by
             qualitative Polymerase Chain Reaction (PCR) (reverse transcriptase [RT]-PCR), or other
             commercial or public health assay in any specimen during the current hospital
             admission prior to randomization.

          -  Illness (symptoms) of any duration, and the following:

               1. Radiographic infiltrates by imaging (chest x-ray, computerized tomography [CT]
                  scan, etc.), and

               2. Requiring mechanical ventilation and/or supplemental oxygen

          -  Subjects with no limitation of therapeutic effort (decision on the status and future
             of the subject).

          -  Female subjects of child-bearing potential must have a negative test for pregnancy
             blood or urine human chorionic gonadotropin (HCG)-based assay at Screening/Baseline
             Visit.

        Exclusion Criteria:

          -  Clinical evidence of any significant acute or chronic disease that, in the opinion of
             the investigator, may place the subject at undue medical risk.

          -  The subject has had a known serious anaphylactic reaction to blood, any blood-derived
             or plasma product or methylene blue.

          -  A medical condition in which the infusion of additional fluid is contraindicated.

          -  Shock unresponsive to fluid challenge and/or multiple vasopressors and accompanied by
             multiorgan failure considered by the Principal Investigator not able to be reversed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mireia Torres</last_name>
    <phone>+34 93 5710500</phone>
    <email>mireia.torres@grifols.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elsa Mondou</last_name>
    <phone>919-316-2079</phone>
    <email>elsa.mondou@grifols.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricard Ferrer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Manez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Caballero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Llamas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Sanchez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Quintana, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Alegre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Canarias</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan j Jimenez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago -CHUS</name>
      <address>
        <city>Santiago</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristobal Galban, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus Disease</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

